New diagnosis of multiple myeloma in a patient with mantle cell lymphoma: Shared genetic factors or simple coincidence?  by Sikuyayenga, Mutende J. et al.
Leukemia Research Reports 1 (2012) 7–8Contents lists available at SciVerse ScienceDirectLeukemia Research Reports2213-04
http://d
Abbre
ﬂuorode
sone; V
colony-
variable
n Corr
E-mjournal homepage: www.elsevier.com/locate/lrrCase ReportNew diagnosis of multiple myeloma in a patient with mantle cell lymphoma:
Shared genetic factors or simple coincidence?Mutende J. Sikuyayenga n, Craig B. Reeder, Joseph R. Mikhael
Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ, United Statesa r t i c l e i n f o
Article history:
Received 27 July 2012
Received in revised form
14 September 2012
Accepted 18 September 2012
Available online 10 November 2012
Keywords:
Multiple myeloma
Mantle cell lymphoma
t(11;14)(q13;q32)89 & 2012 Elsevier Ltd.
x.doi.org/10.1016/j.lrr.2012.09.003
viations: MM, multiple myeloma; MCL, m
oxyglucose; VCD, velcade (bortezomib) cyclo
RD, velcade revlimid (lenalidomide) dexamet
stimulating factor; PBSCT, peripheral blood st
, diverse, joining (region); IgH, immunoglobi
esponding author. Tel.: þ1 480 301 9824; fa
ail address: Sikuyayenga.mutende@mayo.edu
Open access under CC Ba b s t r a c t
Multiple Myeloma and Mantle Cell Lymphoma are well deﬁned hematological malignancies. Under-
standing of their pathogeneses has led to new therapies and increased survival. We report on a 64-yr-
old female who was diagnosed with mantle cell lymphoma in 2003, then multiple myeloma in 2010.
We identiﬁed only few other cases of concomitant MM and MCL. We also explored the importance of
t(11;14)(q13;q32). The development of these two disorders in the same patient may simply be due to
chance; however, it may also represent a common genetic hit affecting the B-cell population leading to
development of two different malignancies.
& 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.Multiple myeloma and mantle cell lymphoma are well deﬁned
B-cell malignancies with signiﬁcant disease burden worldwide.
Understanding of the pathogenesis of both entities has improved
over the years, leading to new therapies and improved survival
rates.1,2 The hallmark of MCL is t(11;14)(q13;q32); this genetic
alteration leads to overexpression of cyclin D1, an important
regulator of the cell cycle.3 While the same translocation and
overexpression of cyclin D1 has been recognized in a subset of
patients with MM, its role in the pathogenesis of myeloma is still
undetermined.4 The occurrence of MCL and MM in the same
patient is very rare. To our knowledge, there are only limited case
reports of MCL and MM affecting the same patient.5–9 Here we
report a case of MMwhich arose in a patient previously diagnosed
and successfully treated for MCL. We also review literature to
explore the relationship, if any, between these two entities to
understand how genetic factors might contribute to their devel-
opment in a single individual.
A 64 yr-old female with no signiﬁcant past medical history
developed lymphadenopathy and splenomegaly in the 1970s. By
patient report, all pathology studies obtained following splenect-
omy were negative for malignancy. In 2003 the patient presented
again with generalized lymphadenopathy. A diagnosis of MCL was
made; the bone marrow was not involved. After six cycles ofantle cell lymphoma; FDG,
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years. In 2007, routine follow-up imaging demonstrated recur-
rence of lymphadenopathy. An axillary lymph node biopsy was
again positive for a monoclonal B cell population characteristic of
MCL. Flow cytometry conﬁrmed a clone expressing CD5, CD19,
CD20, FMC-7 and kappa light chain. FISH conﬁrmed a CCND1/IgH
rearrangement in 63% of cells. There was no evidence of a plasma
cell component. The patient completed six cycles of bortezomib,
pentostatin, and rituximab. She was then placed on maintenance
therapy with rituximab every three months until September
2010.
Shortly after her last dose of rituximab she developed general-
ized body aches, fatigue, headache, dizziness, and epistaxis.
Physical examination was unremarkable except for right tonsillar
prominence. Extensive laboratory studies revealed normocytic
anemia, mild hypercalcemia, elevated total protein, high serum
viscosity, and normal renal function. Special protein studies
showed a monoclonal IgM kappa protein, an M-spike of 4 gm/dL
and IgM of 7060 mg/dl. Plasmapheresis was started for hyper-
viscosity syndrome. PET/CT scan showed no diffuse lymphadeno-
pathy or bony lesion; there was a 2-cm mass in the right palatine
tonsil region with increased FDG uptake. Biopsy was planned, and
then canceled given increased risk of bleeding due to high serum
viscosity. Bone marrow aspiration and biopsy showed a hyper-
cellular marrow (60%) with 50% clonal plasma cells consistent
with multiple myeloma. There was no evidence of mantle cell
lymphoma or lymphoplasmacytic lymphoma. Repeat studies by
different institutions conﬁrmed kappa light chain positive mye-
loma with negative immunostaining for CD5, CD19, CD20, and
CD56. Cytogenetic studies revealed a 46, XX female karyotype and
the presence of t(11;14) by FISH as the only genetic aberration.
M.J. Sikuyayenga et al. / Leukemia Research Reports 1 (2012) 7–88She had a good response to therapy after receiving four cycles of
bortezomib, cyclophosphamide, and dexamethasone (VCD) with
the M-spike dropping to as low as 1.2, quantitative IgM to
2060 mg/dl, and plasma cells to only 10 % in the bone marrow.
She underwent peripheral blood stem cell (PBSC) collection;
6 million CD34þ cells were collected after administration Plerix-
afor in addition to high dose G-CSF. Additional three cycles of VCD
were given, then cyclophosphamide was replaced by lenalido-
mide due to poor response. After four cycles of VRD the patient
underwent successful autologous PBSCT. Both MM and MCL are
currently in remission.
In a letter to the editor of Leukemia Research, Dasanu reported
the case of a 55-yr-old male diagnosed with t(11;14)þ IgG-
lambda MM, who presented with enlarged lymph nodes six years
later. Biopsy was consistent with CD5-negative MCL.5 In 1999,
Yamaguchi conducted clonal relationship analysis on myeloma
and lymphoma cells obtained from a 76-yr-old male diagnosed
with CD5-positive MCL and IgG-kappa MM. He concluded that
there was no clonal relationship between the two diseases.6
However, a recent study of seven MCL cases presenting with a
plasma cell component demonstrated that in ﬁve patients both
MCL and plasma cell clones had identical restriction fragments,
and thus a common clonal origin.9
In addition to the fact that both diseases arise from B cells,
these two malignancies also share some other features including
the presence of t(11;14) and the overexpression of cyclin D1. It is
suggested that overexpression of this important cell cycle reg-
ulator is crucial for malignant cell survival in MCL; on the other
hand, the importance of t(11;14) in the pathogenesis of MM
remains uncertain. Some investigations concluded that cyclin D1
expression was not essential for the pathogenesis of MM. For
example, Fiancette et al. showed that deregulation of CCND1 gene
and overexpression of cyclin D1 did not result in accelerated
tumorigenesis in mice; thus, concluding that cyclin D1 expression
may simply represent a ‘‘single hit’’ in B-cell malignancies and
may not in itself be adequate for oncogenesis.10 However,
Marsaud and her partners injected cells that had been genetically
modiﬁed to express cyclin D1 into immunocompromised mice to
test the oncogenic property of this factor. The mice developed
malignant tumors at the injection site demonstrating that cyclin
D1 is indeed oncogenic.11 In fact, another animal study also
illustrated the oncogenic nature of cyclin D1 expression and
proposed a possible mechanism through its nuclear-retention.12
More recently, Tchakarska and colleagues showed that cyclin D1
might also act by inhibition of mitochondrial metabolism which
could potentially lead to loss of apoptosis and, therefore, uncon-
trolled growth.13 It is important to point out that although the
t(11;14)(q13;q32) can be present in both MCL and MM; the
genetic background is different. In the ﬁrst, the translocation
results from VDJ recombinations, and in the later, it is the product
of errors in somatic hypermutation within the IgH switch
regions.14,15 Unfortunately, molecular studies of the cancer cells
for clonal relationship could not be undertaken in our patient
because of lack of adequate MCL sample. Sequencing of the
IgH regions from the two cell groups would have been very
informative. It is however interesting to speculate about a
possible composite disease based on multiple facts; the CD19negativity which is uncommon in pure plasma cell dyscrasias;
high M-spike and other features of multiple myeloma, but poor
response to bortezomib as sometimes seen in MCL.
The rarity of concomitant diagnosis of MCL and MM makes it
difﬁcult to investigate a possible association. Our patient has two
kappa-restricted malignancies with a common genetic mutation,
which may suggest a true association; however, in the absence of
clonality studies, we can only wonder about their clonal origin.
While the investigation done by Yamaguchi and his colleagues in
the case reported above concluded that there was no clonal
relationship; the studies performed by Visco and colleagues
showed the same clonal origin in ﬁve cases of MCL with plasma
cell component. Although the question about the clinical signiﬁ-
cance of this genetic aberration shared by MM and MCL seems to
be settled, its role in tumorigenesis is an ongoing area of
investigation. Further studies may lead to better understanding
of the pathogenesis of both MM and MCL and potentially reveal
new targets for therapy.References
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